India’s first natively developed COVID-19 vaccine, Covaxin is going fir a trail among those aged between 2 and 18 at the AIIMS here on Monday.

The trial on children has already been tested at AIIMS Patna to see if the Bharat Biotech jab is suitable for children. The trial is to be conducted on 525 healthy volunteers. In the trial, the vaccine will be given by intramuscular route in two doses at day 0 and day 28. At the same time, Dr Sanjay Rai, Professor at the Centre for Community Medicine at AIIMS, said “The screening of children for conducting trial of Covaxin has started. Participants would be given the vaccine after their screening reports come.” India’s drug regulator had granted permission for conducting the phase 2/3 clinical trial of Covaxin in the age group 2 to 18 years on May 12. The government last week cautioned the coronaviris impact on children can increase among if there is a change in virus behaviour or epidemiology dynamics, and said preparations are being strengthened to deal with any such situation. A national expert group has been formed to review COVID-19 infections in children. NITI Aayog Member (Health) V K Paul had said at a press conference that 'The group has examined signs which were not available four-five months before.’ Further it was asked if the Pfizer vaccine comes to India, will it be considered for children between the age of 12 and 15 years as being approved by the UK.

Paul said, Zydus Cadila’s vaccine is already being tested in children.

Kotak Mahindra announces introduction of a Pandemic Benevolent Policy for its Employees

Terrorists attack on 'CRPF' in Pulwama, all CRPF personnel said to be safe

Get ready to curb the Corona third wave : Chief Secretary